Dronedarone in High-Risk Permanent Atrial Fibrillation
Open Access
- 15 December 2011
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 365 (24), 2268-2276
- https://doi.org/10.1056/nejmoa1109867
Abstract
Dronedarone restores sinus rhythm and reduces hospitalization or death in intermittent atrial fibrillation. It also lowers heart rate and blood pressure and has antiadrenergic and potential ventricular antiarrhythmic effects. We hypothesized that dronedarone would reduce major vascular events in high-risk permanent atrial fibrillation. We assigned patients who were at least 65 years of age with at least a 6-month history of permanent atrial fibrillation and risk factors for major vascular events to receive dronedarone or placebo. The first coprimary outcome was stroke, myocardial infarction, systemic embolism, or death from cardiovascular causes. The second coprimary outcome was unplanned hospitalization for a cardiovascular cause or death. After the enrollment of 3236 patients, the study was stopped for safety reasons. The first coprimary outcome occurred in 43 patients receiving dronedarone and 19 receiving placebo (hazard ratio, 2.29; 95% confidence interval [CI], 1.34 to 3.94; P=0.002). There were 21 deaths from cardiovascular causes in the dronedarone group and 10 in the placebo group (hazard ratio, 2.11; 95% CI, 1.00 to 4.49; P=0.046), including death from arrhythmia in 13 patients and 4 patients, respectively (hazard ratio, 3.26; 95% CI, 1.06 to 10.00; P=0.03). Stroke occurred in 23 patients in the dronedarone group and 10 in the placebo group (hazard ratio, 2.32; 95% CI, 1.11 to 4.88; P=0.02). Hospitalization for heart failure occurred in 43 patients in the dronedarone group and 24 in the placebo group (hazard ratio, 1.81; 95% CI, 1.10 to 2.99; P=0.02). Dronedarone increased rates of heart failure, stroke, and death from cardiovascular causes in patients with permanent atrial fibrillation who were at risk for major vascular events. Our data show that this drug should not be used in such patients. (Funded by Sanofi-Aventis; PALLAS ClinicalTrials.gov number, NCT01151137.)Keywords
This publication has 23 references indexed in Scilit:
- A propensity score-adjusted retrospective comparison of early and mid-term results of mitral valve repair versus replacement in octogenariansEuropean Heart Journal, 2010
- Analysis of Stroke in ATHENA: A Placebo-Controlled, Double-Blind, Parallel-Arm Trial to Assess the Efficacy of Dronedarone 400 mg BID for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial FlutterCirculation, 2009
- Effect of Dronedarone on Cardiovascular Events in Atrial FibrillationThe New England Journal of Medicine, 2009
- Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on Atrial FibrillationEuropean Heart Journal, 2008
- Dronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or FlutterThe New England Journal of Medicine, 2007
- Progressive Nature of Paroxysmal Atrial Fibrillation-Observations From a 14-Year Follow-up Study-Circulation Journal, 2004
- Effects of a New Amiodarone-Like Agent, SR 33589, in Comparison to Amiodarone, D,L-Sotalol, and Lignocaine, on Ischemia-Induced Ventricular Arrhythmias in Anesthetized PigsJournal of Cardiovascular Pharmacology, 1995
- Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the β‐adrenoceptor and adenylate cyclase in rat heartBritish Journal of Pharmacology, 1995
- SR 33589, a New Amiodarone-Like AgentJournal of Cardiovascular Pharmacology, 1995
- SR 33589, a new amiodarone-like antiarrhythmic agent: anti-adrenoceptor activity in anaesthetized and conscious dogsEuropean Journal of Pharmacology, 1995